|
|
|
|
|
|
|
|
|
|
"Bevacizumab (Avastin) has failed to demonstrate statistically significant improvements in overall survival (OS) for women with recurrent ovarian cancer in 2 recent clinical trials, but those results may be affected by factors not related to the drug’s efficacy, according to Michael J. Birrer, MD, PhD......
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.